Monoclonal antibody · Cytotoxic, directed at CD38 · developed by Sanofi Aventis Us
Isatuximab is an IgG1-derived monoclonal antibody that binds CD38 on hematopoietic and tumor cells, including multiple myeloma cells. It induces tumor cell apoptosis and immune effector killing through ADCC, ADCP and complement-dependent cytotoxicity, and inhibits CD38's ADP-ribosyl cyclase activity. It is studied in monoclonal gammopathy.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jul 7, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04643002 | Phase 1/2 | Plasma Cell Myeloma Refractory | Recruiting | SNY |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Monoclonal Gammopathy
Updated Nov 15, 2026. Something wrong or missing? Report it on the SNY page.
See SNY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SNY catalysts and pipeline →